How Does One Decide Which Tyrosine Kinase Inhibitor To Use for the Initial Treatment of Chronic-Phase Chronic Myeloid Leukemia?

Tyrosine Kinase ◽

Initial Treatment ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

17 / An Observational Study of Survival in Patients With Chronic-Phase Chronic Myeloid Leukemia (CML-CP) After 1, 3, and 5 Years of Tyrosine Kinase Inhibitor (TKI) Therapy (SIMPLICITY)

10.26226/morressier.5b3b802cb1b87b000eced8f4 ◽

2018 ◽

Author(s):

Mauro Michael J.

Keyword(s):

Observational Study ◽

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

An Observational Study of Survival in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) After 1, 3, and 5 Years of Tyrosine Kinase Inhibitor (TKI) Therapy (SIMPLICITY)

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2018.07.105 ◽

2018 ◽

Vol 18 ◽

pp. S229

Author(s):

Mauricette Michallet ◽

Jorge Cortes ◽

Carlo Gambacorti-Passerini ◽

Rüdiger Hehlmann ◽

Loretta A. Williams ◽

...

Keyword(s):

Observational Study ◽

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Comparing the efficacy of generic Imatinib formulations with the original Imatinib as the frontline tyrosine kinase inhibitor in chronic phase chronic myeloid leukemia.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e18024 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e18024-e18024 ◽

Cited By ~ 1

Author(s):

Fatih Demirkan ◽

Omur Gokmen Gokmen Sevindik ◽

Aysegul Karaman ◽

Inci Alacacioglu ◽

Serife Medeni Solmaz ◽

...

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2017.09.004 ◽

2017 ◽

Vol 17 (12) ◽

pp. e71-e73 ◽

Cited By ~ 2

Author(s):

Vamsi K. Kota ◽

Jee Hyun Kong ◽

Martha Arellano ◽

Fuad El Rassi ◽

Manila Gaddh ◽

...

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Second Generation ◽

Kinase Inhibitor ◽

Chronic Phase ◽

Newly Diagnosed

Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia

Haematologica ◽

10.3324/haematol.2014.104075 ◽

2014 ◽

Vol 99 (7) ◽

pp. 1197-1203 ◽

Cited By ~ 73

Author(s):

D. Rea ◽

T. Mirault ◽

T. Cluzeau ◽

J.-F. Gautier ◽

F. Guilhot ◽

...

Keyword(s):

Tyrosine Kinase ◽

Early Onset ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Chronic Phase ◽

2Nd Generation

Symptoms Following Discontinuation of Tyrosine Kinase Inhibitor (TKI) Therapy After Achieving an Adequate Response in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2018.07.091 ◽

2018 ◽

Vol 18 ◽

pp. S221-S222

Author(s):

Ellen K. Ritchie ◽

Islam Sadek ◽

Irina Pivneva ◽

Annie Guerin ◽

Dominick Latremouille-Viau ◽

...

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Chronic Phase ◽

Adequate Response

Variables associated with patient-reported symptoms in persons with chronic phase chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Medicine ◽

10.1097/md.0000000000018079 ◽

2019 ◽

Vol 98 (48) ◽

pp. e18079 ◽

Cited By ~ 2

Author(s):

Lu Yu ◽

Xiaojun Huang ◽

Robert Peter Gale ◽

Haibo Wang ◽

Qian Jiang

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Chronic Phase ◽

Inhibitor Therapy ◽

Tyrosine Kinase Inhibitor Therapy ◽

Patient Reported

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-014-1845-6 ◽

2014 ◽

Vol 141 (5) ◽

pp. 887-899 ◽

Cited By ~ 43

Author(s):

Katerina Machova Polakova ◽

Vojtech Kulvait ◽

Adela Benesova ◽

Jana Linhartova ◽

Hana Klamova ◽

...

Keyword(s):

Tyrosine Kinase ◽

Deep Sequencing ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Chronic Phase ◽

Kinase Domain ◽

Kinase Domain Mutations ◽

Inhibitor Treatment

Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

American Journal of Hematology ◽

10.1002/ajh.25306 ◽

2018 ◽

Vol 94 (1) ◽

pp. 46-54 ◽

Cited By ~ 4

Author(s):

Rüdiger Hehlmann ◽

Jorge E. Cortes ◽

Teresa Zyczynski ◽

Carlo Gambacorti-Passerini ◽

Stuart L. Goldberg ◽

...

Keyword(s):

Clinical Practice ◽

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Chronic Phase ◽

Routine Clinical Practice

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study

International Journal of Hematology ◽

10.1007/s12185-014-1566-2 ◽

2014 ◽

Vol 99 (5) ◽

pp. 616-624 ◽

Cited By ~ 30

Author(s):

Michele Baccarani ◽

◽

Brian J. Druker ◽

Susan Branford ◽

Dong-Wook Kim ◽

...

Keyword(s):

Tyrosine Kinase ◽

Initial Dose ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Philadelphia Chromosome ◽

Chronic Phase ◽

Term Response